28 Steigler P, Chhiba M, Francis V, et al. T cell responses to Mycobacterium indicus pranii immunotherapy and adjunctive glucocorticoid therapy in tuberculous pericarditis. Vaccine X 2022 11: 100177. 29 Vilaplana C, Montane E, Pinto S, et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010 28: 1106–1116. 30 Nell AS, d’Lom E, Bouic P, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One 2014 9: e89612. 31 von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette–Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010 24: 675–685. 32 von Reyn CF, Lahey T, Arbeit RD, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. PLoS One 2017 12: e0175215. 33 Munseri P, Said J, Amour M, et al. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: a randomized controlled, double-blind phase 2b trial. Vaccine 2020 38: 7239–7245. 34 Spertini F, Audran R, Chakour R, et al. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med 2015 3: 953–962. 35 Tameris M, Mearns H, Penn-Nicholson A, et al. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med 2019 7: 757–770. 36 Loxton AG, Knaul JK, Grode L, et al. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vaccine Immunol 2017 24: 1472–1483. 37 Grode L, Ganoza CA, Brohm C, et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013 31: 1340–1348. 38 Cotton MF, Madhi SA, Luabeya AK, et al. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect Dis 2022 22: 1472–1483. 39 Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 2018 379: 138–149. 40 WHO. Global Tuberculosis Report 2022. Geneva, WHO, 2022. 41 Wang J, Thorson L, Stokes RW, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004 173: 6357–6365. 42 Xing Z, McFarland CT, Sallenave J-M, et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 2009 4: e5856. 43 Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011 29: 5203–5209. 44 Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020 396: 467–478. 45 Saramago S, Magalhães J, Pinheiro M. Tuberculosis vaccines: an update of recent and ongoing clinical trials. Appl Sci 2021 11: 9250. 46 Khoshnood S, Heidary M, Haeili M, et al. Novel vaccine candidates against Mycobacterium tuberculosis. Int J Biol Macromol 2018 120: 180–188. 47 Woodworth JS, Clemmensen HS, Battey H, et al. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette–Guerin. Nat Commun 2021 12: 6658. 48 Brandt L, Elhay M, Rosenkrands I, et al. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000 68: 791–795. 49 Kochenderfer JN, Chien CD, Simpson JL, et al. Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8 +T cell responses. J Immunol 2006 177: 8860–8873. 50 Gillard P, Yang PC, Danilovits M, et al. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study. Tuberculosis (Edinb) 2016 100: 118–127. 51 Patel N, Deshpande MM, Shah M. Effect of an immunomodulator containing mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 2002 100: 191–193. 52 Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006 86: 273–289. https://doi.org/10.1183/2312508X.10024922 175 RECENT ADVANCES IN VACCINES |A.K.K. LUABEYA ET AL.